Glenmark Pharmaceuticals Ltd. share price target

9 US sales saw steady yoy growth of 10% despite 57% price erosion in base portfolio; GNPguidesforstrongH2ledbypickupinrecent/newlaunches Domesticformulationswereaheadofexpectationswith27%yoyimprovementdueto...

ff Management expects slowdown in Venezuela as it is hard to obtain the requisite import license. Potential threat of significant devaluation in Venezuela puts US$2030mn of company's exposure there at risk. As per our estimates, Venezuela contributed ~6% of FY15 profits. Factoring in the devaluation in FY17E, we...

company maintained its sales growth guidance of 1820% and EBITDA of ~Rs 17.5bn (implying ~22% margin) on a presumed ramp up in US generic sales and continued momentum in domestic formulations. However, modest US sales growth (8.5%) in Q1...

broadbased improvement in US sales (20%), domestic formulations (1719%), and in EuropeandROWmarkets.IttargetsanEBITDAofRs17.5bn,implyingamarginof~22% (lower than our estimate of 22.7%) and tax incidence of 2324% (we factored 22%). The...

Background: Tarka is a hypertension drug with market size of US$70mn. Glenmark had launched the drug "at-risk" in June 2010. However, the Federal Jury ruled against Glenmark in January 2011 and awarded Abbott US$16mn in...

Glenmark pharma's (GNP) Q1FY14 revenues grew 19% YoY to Rs. 1238.2 cr driven by 33% growth in Latin America (specialty business), 25% growth in RoW markets, 26% growth in API...

Glenmark Pharmaceuticals Ltd(GPL) is a research driven, integrated pharma company that has presence in both Generic and API business. The company is a leading player in the discovery of new molecules both new chemical...